Table 2. Comparison of BM, PB, cytogenetic, and molecular findings in patients without BM fibrosis to those with any amount of BM fibrosis.
| MF-0 (N = 38) | MF1+ (N = 45) | P | |||
|---|---|---|---|---|---|
| Mean BM Cellularity (Range) | 80 | (40–100) | 85 | (40–100) | 0.1 |
| BM Megakaryocytes | |||||
| Increased | 17 | 45% | 27 | 60% | 0.04 |
| Decreased | 3 | 8% | 8 | 18% | |
| Adequate | 18 | 47% | 10 | 22% | |
| Mean BM Smear Blasts (Range) | 8.40 | (1–15) | 8.70 | (1–16) | |
| Blasts estimated by IHC (Number of cases) | 1/38 | 3% | 4/45 | 9% | 0.2 |
| Mean BM Smear Monocytes (Range) | 18 | (3–34) | 18 | (2–35) | 0.9 |
| Means (Range) | |||||
| WBC [x 109 cells/ L] | 19.5 | (3.7–53.1) | 29.5 | (4.1–170.2) | 0.06 |
| PB Blasts (%) | 0.4 | (0–8) | 0.9 | (0–7) | 0.07 |
| Abs Mono [x 109 cells/ L] | 4,806.2 | (909–22833) | 9,881.6 | (988–131054) | 0.1 |
| Hgb [g/ dL] | 10.8 | (5–14.9) | 10.8 | (6.4–15) | 0.9 |
| MCV [fL] | 91.5 | (68.7–114) | 91.8 | (74–117) | 0.9 |
| Plt [x109 cells/ L] | 122 | (32–296) | 107.5 | (8–504) | 0.4 |
| Cytogenetic risk stratification | N = 37 | N = 43 | 0.8 | ||
| low (normal karyotype, isolated -Y) | 31 | 84% | 34 | 79% | |
| intermediate (all other abnormalities) | 4 | 11% | 5 | 12% | |
| high (complex karyotype, +8, abnormalities of 7) | 2 | 5% | 4 | 9% | |
| Molecular findings | |||||
| JAK2 V617F status | N = 27 | N = 35 | |||
| negative | 23 | 85% | 33 | 94% | 0.38 |
| positive | 4 | 15% | 2 | 6% | |
| not tested | 11 | 10 | |||
| MPL exon 10 mutation | N = 13 | N = 15 | |||
| negative | 13 | 15 | 1 | ||
| positive | 0 | 0 | |||
| not tested | 25 | 30 | |||
| CALR exon 9 mutation | N = 5 | N = 2 | |||
| negative | 5 | 2 | 1 | ||
| positive | 0 | 0 | |||
| not tested | 33 | 43 | |||